Product Reports Resources Pricing Login Book a demo

Arvinas

Biotech & Life Sciences · New Haven, United States · Founded 2013 · IPO 2018

Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat debilitating and life-threatening diseases. The company operates in the biotechnology sector and primarily serves patients suffering from conditions caused by disease-causing proteins. Arvinas leverages its proprietary technology platform to create proteolysis targeting chimeras (PROTAC® protein degraders), which are designed to harness the body's natural protein disposal system to selectively degrade harmful proteins. The company's business model revolves around the discovery, development, and commercialization of these novel therapies. Arvinas generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, as well as through the potential commercialization of its own drug candidates. Arvinas operates in the global biopharmaceutical market, targeting a range of diseases including cancer and neurodegenerative disorders. The company aims to improve patient outcomes by providing targeted, effective treatments that address the underlying causes of these diseases. Keywords: protein degradation, PROTAC, biopharmaceutical, clinical-stage, biotechnology, disease-causing proteins, innovative therapies, cancer, neurodegenerative disorders, proprietary technology.

Revenue $100–500M
Headcount 100–500
Total funding $100–500M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

12 investors on Arvinas's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage
5AM Ventures
Canaan
Connecticut Innovations
Elm Street Ventures
RA Capital Management
New Leaf Venture Partners
OrbiMed
Series B+ 5 investors entered at this stage
Nextech Invest
Nextech Venture
Deerfield
Sirona Capital
Hillhouse Capital

Global footprint

Where Arvinas has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States98.4%
🇬🇧 United Kingdom1.2%
🇦🇹 Austria0.4%
3 countries shown
Web traffic by country
18K monthly visits
across markets
🇺🇸 United States57.2%
🇬🇧 United Kingdom13.9%
🇮🇳 India12.8%
🇨🇦 Canada7.2%
🇯🇵 Japan6.7%
Top 5 markets shown

Talent graph

The shape of Arvinas's talent

Dealroom maps Arvinas's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 standout operatorsDealroom-flagged across the org
2 AI specialistsincl. 1 core researchers
305 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Arvinas's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$128M patent portfolio · 115 active families

Estimated portfolio value
$128M
165.8× larger than top peer POINT Biopharma ($771k)
115 active patent families
Where Arvinas innovates Androgen Receptor GeneCancer researchCereblonDiseaseMolecular biology

Where Arvinas concentrates vs peers

Each axis is a top-10 topic across Arvinas and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Arvinas

An AI-synthesized read of the highest-engagement posts about Arvinas on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arvinas on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles